WIN55,212-2, A Cannabinoid Receptor Agonist, Protects Against Nigrostriatal Cell Loss In The MPTP Mouse Model Of Parkinson’s Disease

Parkinson's Disease

Key Findings

Our data indicate that agonism at CB2 cannabinoid receptors protects against MPTP-induced nigrostriatal degeneration by inhibiting microglial activation/infiltration and suggest that CB2 receptors represent a new therapeutic target to slow the degenerative process occurring in PD.

Information and Links


Link: WIN55,212-2, A Cannabinoid Receptor Agonist, Protects Against Nigrostriatal Cell Loss In The MPTP Mouse Model Of Parkinson’s Disease

Year: 2009

DOI: 10.1111/j.1460-9568.2009.06764.x


Ratings

(How Ratings Work)

Parkinson's Disease — 2


Possible to probable range of efficacy of cannabis for treatment of Parkinson's Disease according to the results found in this study.

Drugs Used

WIN55,212-2

JWH015